Compare Canopy Growth Corp (CGC) vs HCA Health Inc (HCA) Price & Performance

Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.

The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.

HCA Healthcare stock trades at $390.74, down 3.9% following a lowered 2026 profit outlook. The company maintains strong fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats, though technical indicators show bearish momentum. Recent news highlights challenges from payer mix shifts and rising uninsured patients, creating near-term headwinds despite long-term capacity expansion initiatives.

The stock presents a valuation opportunity with a P/E of 13.5x below industry averages, supported by analyst consensus target of $481.80. Key risks include execution on guidance and healthcare reimbursement pressures, but institutional sentiment remains positive with 63% buy ratings, suggesting potential recovery once near-term uncertainties resolve.